pre-IPO PHARMA

COMPANY OVERVIEW

None


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jun 17, 2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer


Jun 10, 2021

Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development


Feb 25, 2021

Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform


Oct 16, 2020

Cullgen Announces “Featured Article” Publication of First in Class TRK Protein Degraders in Journal of Medicinal Chemistry


Apr 7, 2020

Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry


For More Press Releases


Google Analytics Alternative